Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)

  • Details

ClinicalTrials.gov ID: NCT04197986
Diagnosis Type: NA
USOR Number: 19094

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Colon Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Endometrial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Pancreatic Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Solid Tumors

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100) (20170543)

  • Details

ClinicalTrials.gov ID: NCT03600883
Diagnosis Type: NA
USOR Number: 19024

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lung Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Leukemia

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

  • Details

ClinicalTrials.gov ID: NCT03206918
Diagnosis Type: NA
USOR Number: 18263

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lymphomas

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

  • Details

ClinicalTrials.gov ID: NCT03206918
Diagnosis Type: NA
USOR Number: 18263

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lymphomas

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life: A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents (D8220R00004)

  • Details

ClinicalTrials.gov ID: NCT03816683
Diagnosis Type: NA
USOR Number: 18127

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Bladder Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Details

ClinicalTrials.gov ID: NCT03955913
Diagnosis Type: NA
USOR Number: 19032

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

  • Details

ClinicalTrials.gov ID: NCT03955913
Diagnosis Type: NA
USOR Number: 19032

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)

  • Details

ClinicalTrials.gov ID: NCT03975647
Diagnosis Type: NA
USOR Number: 19054

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

  • Details

ClinicalTrials.gov ID: NCT03390504
Diagnosis Type: NA
USOR Number: 17133

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Breast Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer (SGNLVA-002)

  • Details

ClinicalTrials.gov ID: NCT03310957
Diagnosis Type: NA
USOR Number: 18004

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Biliary Cancer

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: NA
USOR Number: 18264

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Solid Tumors

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lymphomas

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

AN OPEN-LABEL, MULTICENTER, PHASE I/IB TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA (GO29781)

  • Details

ClinicalTrials.gov ID: NCT02500407
Diagnosis Type: Non-Hodgkins
USOR Number: 18187

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Lymphomas

Clinical Trial at: Rocky Mountain Cancer Centers - Boulder

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Hodgkins
USOR Number: 11282

  • Practice Details

4715 Arapahoe Avenue
Boulder, Colorado 80303
552.13 mi. away
P: (303) 385-2000

More Details View Practice Page

Pages